Future investigations are warranted to explore the use of combining current cancer-debulking therapies with novel persistence-eliminating PRMT1 inhibitors in more extensive disease settings beyond EGFRmut and KRASG12C lung cancer. Here, PRMT1 is linked to lung carcinoma.